SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 4.99% Stake in Can-Fite BioPharma Ltd.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a beneficial ownership of 4.99% of Can-Fite BioPharma Ltd.'s common stock as of December 31, 2024.

Summary

• Armistice Capital, LLC and Steven Boyd, collectively referred to as the 'Reporting Persons,' have filed an Amendment No. 2 to Schedule 13G.
• The filing pertains to their beneficial ownership of Common Stock, par value $0.001 per share, of Can-Fite BioPharma Ltd.
• As of December 31, 2024, the Reporting Persons collectively beneficially own 440,422 shares of Can-Fite BioPharma Ltd.'s common stock.
• This ownership represents 4.99% of the total class of securities.
• Armistice Capital, LLC and Steven Boyd hold shared voting power and shared dispositive power over all 440,422 shares.
• The shares are held in the ordinary course of business and were not acquired for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain subjective language or performance metrics that would indicate a strong positive or negative sentiment.

Positives

• A significant institutional investor, Armistice Capital, LLC, maintains a notable stake (4.99%) in Can-Fite BioPharma Ltd., which can signal confidence in the company's long-term prospects.
• The filing explicitly states that the shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control, suggesting a passive investment approach.

Management Comments

• Armistice Capital, LLC is the investment manager of Armistice Capital Master Fund Ltd., the direct holder of the Shares, and exercises voting and investment power over the securities.
• Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities held by the Master Fund.
• The Master Fund specifically disclaims beneficial ownership of the securities by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

Industry Context

This filing is a routine disclosure of beneficial ownership by an institutional investor in a biopharmaceutical company. It does not provide specific insights into broader industry trends but reflects an investment firm's position in the sector.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holding, which can influence investor confidence and perception of the company's stock.

Key Dates

Keywords

Can-Fite BioPharma Ltd., Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Management, Biopharma, Institutional Investor